Bristol Myers Squibb plans to discuss marketing applications with both the FDA and EMA.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• EMA →

  Japanese vocalist of the group DUSTCELL

  Nothing else this week.

• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09

Related events

• FDA approval enables commercial opportunity involving CBRE Group.Sep 17
• EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.Aug 25
• A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.Thu 13:53
• The FDA is currently reviewing new drug applications for market entry.Jun 22
• Bristol-Myers Squibb holds exclusive commercial rights in Japan after the FDA accepted Zenas's Biologics License Application.Wed 13:05